Actively Recruiting
Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors
Led by University Hospital, Basel, Switzerland · Updated on 2024-12-27
100
Participants Needed
4
Research Sites
122 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main objective of this study is to test if adding the mistletoe extract Iscador® Qu to regular cancer treatment with immune checkpoint inhibitors affects: * The immune system's ability to fight cancer * Safety of the treatment * How well the treatment performs against cancer * How the patient feels during treatment Researchers will compare patients treated with immune checkpoint inhibitors plus Iscador® Qu with patients treated with imune checkpoint inhibitors only.
CONDITIONS
Official Title
Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a locally advanced non-operable or metastatic solid tumor, except skin cancer
- Eligible for standard treatment with immune checkpoint inhibitors, with or without chemotherapy or targeted therapy
- Eligible for treatment with mistletoe preparations (including controlled brain metastases, low-dose prednisolone, no known hypersensitivity)
- Have an ECOG performance status score of 0 to 2
- Male or female aged 18 years or older
- Have not received mistletoe treatment previously
You will not qualify if you...
- Known contraindications to Iscador� Qu or immune checkpoint inhibitors, such as hypersensitivity or active autoimmune disorders
- Diagnosis of skin cancer
- Participation in another investigational drug study within 30 days before joining
- Investigator, their family, employees, or dependents involved in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Kantosspital Baden AG
Baden, Switzerland, 5404
Actively Recruiting
2
Universitätsspital Basel
Basel, Switzerland, 4031
Actively Recruiting
3
Kantonsspital Baselland
Liestal, Switzerland, 4410
Actively Recruiting
4
Tumor- und Brustzentrum Ostschweiz
Sankt Gallen, Switzerland, 9016
Actively Recruiting
Research Team
M
Mascha Binder, Prof. Dr.
CONTACT
B
Benjamin Kasenda, PD Dr. Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here